公开(公告)号：US20230159654A1

公开(公告)日：2023-05-25

申请号：US17534707

申请日：2021-11-24

Applicant: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH

Inventor： Claudine VERMOT-DESROCHES ,  Hélène ROUQUETTE ,  Benoît MILCENT

IPC: C07K16/28 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07K16/2896 ,  A61P35/00 ,  A61P35/02 ,  A61K2039/505

Abstract: Novels antibodies, preferably monoclonal antibodies, or antigen-binding fragments thereof, said antibody or fragment thereof specifically binding to CD5. These antibodies may be used as a medicament, especially in the treatment of diseases in immunomodulation, inflammation, virology, infectiology, autoimmunity and oncology domains. Immune cells and/or cancer cells targeted by the invention are expressing CD5 antigen. These antibodies may be in particular chimeric or humanized. The invention also relates to pharmaceutical compositions, such as immunomodulator, anti-cancerous and anti-infectious compositions, containing such an antibody or antigen-binding fragment and methods of use of these, either for laboratory work, in drug manufacturing, such as in cell therapy cells production, or for medical treatment.

公开(公告)号：US10533046B2

公开(公告)日：2020-01-14

申请号：US15502469

申请日：2015-08-10

Applicant: INTERNATIONAL—DRUG—DEVELOPMENT—BIOTECH ,  UNIVERSITE CLAUDE BERNARD LYON 1 ,  HOSPICES CIVILS DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE LEON BERARD

Inventor： Marie Alexandra Albaret ,  Jean-Jacques Diaz ,  Hichem Claude Mertani ,  Jean-Christophe Saurin ,  Claudine Vermot-Desroches ,  Boris Vuillermoz

IPC: C07K16/18 ,  C07K16/30 ,  A61P35/00 ,  A61K39/395 ,  C07K7/06 ,  A61K39/00 ,  A61K45/06 ,  G01N33/574

Abstract: The present disclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.